atezolizumab,oxaliplatin,5-fluorouracil,l-leucovorin,bevacizumab,trastuzumab deruxtecan,irinotecan,ruxolitinib
daiichi sankyo,roche,astrazeneca,incyte,novartis
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'atezo', 'atezotribe', 't-dxd', 'destiny,crc,02']
great discussion by on destiny-crc02 and atezotribe! t-dxd low dose safer and effective: the way to go when targeting her2+ mcrc #asco23 
Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own